Lv3
392 积分 2021-05-14 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
3天前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
3天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6天前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
Antibody–drug conjugates come of age in oncology
1个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2个月前
已完结
皖公网安备34019202002308
